138 related articles for article (PubMed ID: 32590912)
1. Evaluation of the Efficacy and Safety of the Herbal Formula PM014 in a Cisplatin- and Paclitaxel-Treated Tumor-Bearing Mouse Model.
Lee C; Jeong H; Lee KH; Park S; Gang MJ; Bae SK; Bae H
Integr Cancer Ther; 2020; 19():1534735420924711. PubMed ID: 32590912
[TBL] [Abstract][Full Text] [Related]
2. Standardized herbal extract PM014 alleviates fine dust-induced lung inflammation in mice.
Lee YS; Min D; Park SY; Lee J; Bae H
BMC Complement Med Ther; 2020 Sep; 20(1):270. PubMed ID: 32894124
[TBL] [Abstract][Full Text] [Related]
3. Standardized Herbal Formula PM014 Inhibits Radiation-Induced Pulmonary Inflammation in Mice.
Kim JY; Shin D; Lee G; Kim JM; Kim D; An YM; Yoo BR; Chang H; Kim M; Cho J; Bae H
Sci Rep; 2017 Mar; 7():45001. PubMed ID: 28322297
[TBL] [Abstract][Full Text] [Related]
4. The effects of the standardized herbal formula PM014 on pulmonary inflammation and airway responsiveness in a murine model of cockroach allergen-induced asthma.
Jung KH; Choi HL; Park S; Lee G; Kim M; Min JK; Min BI; Bae H
J Ethnopharmacol; 2014 Aug; 155(1):113-22. PubMed ID: 24879958
[TBL] [Abstract][Full Text] [Related]
5. Thirteen-Week Study of PM014 Subchronic Oral Toxicity in Rats.
Chung HS; Lee H; Bae H
Evid Based Complement Alternat Med; 2014; 2014():189673. PubMed ID: 25104964
[TBL] [Abstract][Full Text] [Related]
6. Herbal Formula, PM014, Attenuates Lung Inflammation in a Murine Model of Chronic Obstructive Pulmonary Disease.
Lee H; Kim Y; Kim HJ; Park S; Jang YP; Jung S; Jung H; Bae H
Evid Based Complement Alternat Med; 2012; 2012():769830. PubMed ID: 22778777
[TBL] [Abstract][Full Text] [Related]
7. Interleukin 12 shows a better curative effect on lung cancer than paclitaxel and cisplatin doublet chemotherapy.
Yue T; Zheng X; Dou Y; Zheng X; Sun R; Tian Z; Wei H
BMC Cancer; 2016 Aug; 16(1):665. PubMed ID: 27549240
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer.
Breathnach OS; Georgiadis MS; Schuler BS; Pizzella P; Llorens V; Kasturi V; Steinberg SM; O'Neil K; Takimoto CH; Johnson BE
Clin Cancer Res; 2000 Jul; 6(7):2670-6. PubMed ID: 10914708
[TBL] [Abstract][Full Text] [Related]
10. Schedule-dependent and -independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murine lung carcinoma in vivo.
Fujimoto S; Chikazawa H
Jpn J Cancer Res; 1998 Dec; 89(12):1343-51. PubMed ID: 10081496
[TBL] [Abstract][Full Text] [Related]
11. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM
Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
Hainsworth JD; Greco FA
Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
[TBL] [Abstract][Full Text] [Related]
13. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer.
Gatzemeier U; von Pawel J; Gottfried M; ten Velde GP; Mattson K; de Marinis F; Harper P; Salvati F; Robinet G; Lucenti A; Bogaerts J; Gallant G
J Clin Oncol; 2000 Oct; 18(19):3390-9. PubMed ID: 11013280
[TBL] [Abstract][Full Text] [Related]
14. Hemocompatibility of folic-acid-conjugated amphiphilic PEG-PLGA copolymer nanoparticles for co-delivery of cisplatin and paclitaxel: treatment effects for non-small-cell lung cancer.
He Z; Shi Z; Sun W; Ma J; Xia J; Zhang X; Chen W; Huang J
Tumour Biol; 2016 Jun; 37(6):7809-21. PubMed ID: 26695149
[TBL] [Abstract][Full Text] [Related]
15. Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer.
Watanabe H; Yamamoto N; Tamura T; Shimoyama T; Hotta K; Inoue A; Sawada M; Akiyama Y; Kusaba H; Nokihara H; Sekine I; Kunitoh H; Ohe Y; Kodama T; Saijo N
Jpn J Clin Oncol; 2003 Dec; 33(12):626-30. PubMed ID: 14769840
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC).
Pirker R; Krajnik G; Zöchbauer S; Malayeri R; Kneussl M; Huber H
Ann Oncol; 1995 Oct; 6(8):833-5. PubMed ID: 8589023
[TBL] [Abstract][Full Text] [Related]
17. A standardized herbal extract PM014 ameliorates pulmonary fibrosis by suppressing the TGF-β1 pathway.
Kim KH; Lee S; Lee H; Shin D; Min D; Kim M; Ryu B; Kim HW; Bae H
Sci Rep; 2018 Nov; 8(1):16860. PubMed ID: 30443024
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel-loaded polymeric micelle (230 mg/m(2)) and cisplatin (60 mg/m(2)) vs. paclitaxel (175 mg/m(2)) and cisplatin (60 mg/m(2)) in advanced non-small-cell lung cancer: a multicenter randomized phase IIB trial.
Lee SY; Park HS; Lee KY; Kim HJ; Jeon YJ; Jang TW; Lee KH; Kim YC; Kim KS; Oh IJ; Kim SY
Clin Lung Cancer; 2013 May; 14(3):275-82. PubMed ID: 23290819
[TBL] [Abstract][Full Text] [Related]
19. A novel herbal formula induces cell cycle arrest and apoptosis in association with suppressing the PI3K/AKT pathway in human lung cancer A549 cells.
Xiong F; Jiang M; Huang Z; Chen M; Chen K; Zhou J; Yin L; Tang Y; Wang M; Ye L; Zhan Z; Duan J; Fu H; Zhang X
Integr Cancer Ther; 2014 Mar; 13(2):152-60. PubMed ID: 24105357
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin/paclitaxel vs cisplatin/teniposide for advanced non-small-cell lung cancer. The EORTC Lung Cancer Cooperative Group. The European Organization for Research and Treatment of Cancer.
Giaccone G; Postmus PE; Splinter TA; Diaz-Puente M; Van Zandwijk N; Scagliotti G; Ardizzoni A; Van Meerbeeck J; Debruyne C
Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):11-4. PubMed ID: 9144684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
